Modulation of inhibitor kappaB kinase/ nuclear factor kappaB signaling during critical illness: a double-edged sword.
Groesdonk
Heinrich Volker
HV
Senftleben
Uwe
U
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D003422:Critical Care / Q000379:methods / Q000592:standards; D016638:Critical Illness / Q000628:therapy; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation; D009102:Multiple Organ Failure / Q000209:etiology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology; D018805:Sepsis / Q000188:drug therapy / Q000276:immunology; D012717:Sesquiterpenes / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016328:NF-kappa B; D012717:Sesquiterpenes; C002669:parthenolide